Phreesia (NYSE:PHR) Hits New 52-Week Low – What’s Next?

Phreesia, Inc. (NYSE:PHR)’s stock price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $13.40 and last traded at $13.34, with a volume of 1379960 shares traded. The stock had previously closed at $13.95.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Citigroup decreased their target price on shares of Phreesia from $29.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, January 9th. BMO Capital Markets assumed coverage on shares of Phreesia in a report on Thursday, November 13th. They issued an “outperform” rating and a $32.00 price objective for the company. Canaccord Genuity Group lowered their price objective on shares of Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, December 9th. DA Davidson cut their target price on Phreesia from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Finally, Wells Fargo & Company started coverage on Phreesia in a research report on Thursday, January 8th. They set an “overweight” rating and a $30.00 price target on the stock. Seventeen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.41.

Phreesia Stock Performance

The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. The stock has a market cap of $745.79 million, a price-to-earnings ratio of -126.44 and a beta of 0.65. The company’s 50-day simple moving average is $16.88 and its 200-day simple moving average is $22.19.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Monday, December 8th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. The company had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The company’s quarterly revenue was up 12.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.25) EPS. Analysts predict that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Insider Transactions at Phreesia

In other news, insider Evan Roberts sold 6,317 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $107,452.17. Following the sale, the insider owned 834,632 shares in the company, valued at $14,197,090.32. The trade was a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Amy Beth Vanduyn sold 2,602 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $44,260.02. Following the completion of the sale, the senior vice president owned 160,238 shares of the company’s stock, valued at approximately $2,725,648.38. This trade represents a 1.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 60,766 shares of company stock worth $1,013,817 in the last three months. Insiders own 5.50% of the company’s stock.

Institutional Trading of Phreesia

A number of hedge funds have recently modified their holdings of PHR. Royal Bank of Canada grew its holdings in shares of Phreesia by 208.8% during the first quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after buying an additional 16,309 shares in the last quarter. AQR Capital Management LLC lifted its stake in Phreesia by 471.2% in the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after acquiring an additional 132,015 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Phreesia by 3.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after acquiring an additional 2,158 shares during the period. NewEdge Advisors LLC grew its stake in Phreesia by 262.7% during the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock valued at $395,000 after acquiring an additional 11,181 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Phreesia by 0.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock valued at $15,336,000 after acquiring an additional 2,402 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.